Anti-PD-1 Antibody in Combination With Low-dose Decitabine in Relapsed

Anti-PD-1 Antibody in Combination With Low-dose Decitabine in Relapsed or Refractory Malignancies

China – Currently recruiting.

The purpose of this study is to assess the feasibility, safety, and efficacy of anti-PD-1 antibody in combination with low-dose decitabine in patients with relapsed or refractory malignancies, including Non-Hodgkin’lymphoma, anti-PD-1-resistant Hodgkin’lymphoma, gastrointestinal cancers, hepatocellular carcinoma, breast cancer, ovarian cancer or lung cancer or renal-cell cancer or pancreatic cancer or bile duct cancer.

Condition Intervention Phase
Malignancies Multiple
Drug: Anti-PD-1 antibody
Drug: Decitabine
Phase 1
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Anti-PD-1 Antibody in Combination With Low-dose Decitabine in Relapsed or Refractory Malignancies: an Open-label Phase I/II Trial

Gavin